Regulation of follicle-stimulating hormone on skeletal muscle lipid deposition, chronic inflammation and insulin resistance and its role on sarcopenic obesity in elderly

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064078

Enrollment

Unknown

Registered

2022-09-26

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenic obesity

Interventions

case series:no intervention

Eligibility

Sex/Gender

All

Age

20 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective lower extremity orthopedic surgery; Subject or their guardian sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Insufficiency of vital organs (heart, liver, kidney, lung); 2. Malignant tumor; 3. Obvious inflammation; 4. Taking hormones (glucocorticoids, estrogens, thyroid hormones); 5. History of gonadectomy; 6. Thyroid and parathyroid diseases; 7. Diabetes.

Design outcomes

Primary

Measure	Time frame
serum level of follicle-stimulating hormone;expression of follicle-stimulating hormone receptor in skeletal muscle;	—

Countries

China

Contacts

Public ContactZhu Yunxia

huaruishi@aliyun.com18930174394

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026